Hepatitis C Testing Global Market Report 2025

The hepatitis C testing market size has grown strongly in recent years. It will grow from $1.24 billion in 2024 to $1.32 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth during the historic period can be credited to the increasing prevalence of hepatitis C, the expansion of public health initiatives, a rise in intravenous drug use, heightened awareness of hepatitis C risks, and increased government funding for infectious disease control.

The hepatitis C testing market size is expected to see strong growth in the next few years. It will grow to $1.68 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to the increasing demand for early disease detection, expanded access to healthcare, a stronger focus on preventive healthcare, support from global health organizations, and government initiatives aimed at hepatitis C elimination. Key trends expected during this period include the adoption of multiplex diagnostic platforms, incorporation of artificial intelligence (AI) in diagnostic tools, a move toward home-based testing kits, enhanced collaboration in test development, and the creation of affordable testing solutions.

The increasing prevalence of hepatitis cases is expected to drive the growth of the hepatitis C testing market moving forward. Hepatitis C is a viral infection that causes liver inflammation and can result in severe liver damage if untreated. The rise in hepatitis cases is largely due to low vaccination rates, leaving many people vulnerable and enabling the virus to spread. Hepatitis C testing enables early detection of the virus, allowing timely treatment to prevent liver damage and serious complications. It also helps identify infected individuals to curb transmission and improve disease management. For example, in April 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental agency responsible for global public health, reported that over 50 million people worldwide are living with chronic hepatitis C infection, with roughly 1 million new cases annually. Thus, the increasing prevalence of hepatitis cases is fueling the growth of the hepatitis C testing market.

Leading companies in the hepatitis C testing market are focusing on developing advanced solutions like dual antigen-antibody diagnostic tests to improve screening and monitoring of the infection. These tests detect viral proteins (antigens) as well as immune response proteins (antibodies), allowing identification of both active and past infections. This dual detection method provides a comprehensive assessment of infection status. For example, in July 2023, Roche Diagnostics India Pvt. Ltd., an India-based provider of diagnostic tests and systems, launched Elecsys HCV Duo - a fully automated immunoassay that simultaneously and independently detects both HCV antigens and antibodies from a single plasma or serum sample. This innovation facilitates early diagnosis, aids patient management, and supports India’s national goal to eliminate hepatitis C through timely and thorough screening.

In June 2022, Liver Care Canada, a healthcare organization focused on liver disease management, partnered with HepCURE Inc. to eliminate hepatitis C in Canada by 2030. This collaboration seeks to incorporate HepCURE’s hepatitis C screening and treatment programs into Liver Care Canada’s services, aiming to improve medication adherence, enhance patient outcomes, and increase access to care in underserved communities. HepCURE Inc., a Canadian non-profit organization dedicated to hepatitis C diagnosis and treatment, has demonstrated a 91% diagnosis rate and 80% linkage to care in Vancouver with its model.

Major players in the hepatitis C testing market are F. Hoffmann-La Roche Ltd., Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Quest Diagnostics Incorporated, Hologic Inc., QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., SD Biosensor INC., QIAGEN N.V., DiaSorin S.p.A., Cepheid, Abcam Plc, OraSure Technologies Inc., Meridian Bioscience Inc., Trivitron Healthcare Private Limited, General Biologicals Corporation, Biogate Laboratories Ltd., Cosara Diagnostics Private Limited, BioGenex Life Sciences Private Limited, and BIOGENIX INC. PVT. LTD.

North America was the largest region in the hepatitis C testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatitis C testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hepatitis C testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hepatitis C testing involves diagnostic techniques used to detect HCV infection or the body's immune response to it. These tests identify both current and past infections, enabling timely treatment. They are especially important for high-risk individuals and assist in monitoring treatment effectiveness. Early diagnosis helps reduce the risk of serious liver complications like cirrhosis and liver cancer.

The primary types of hepatitis C testing include antibody tests, nucleic acid tests, and genotyping tests. Antibody tests detect antibodies in the blood, indicating either a past or ongoing immune response to infections such as hepatitis C. The testing products encompass kits, instruments, reagents, and consumables that utilize various technologies like enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests, polymerase chain reaction (PCR), and next-generation sequencing (NGS). These tests are used in applications such as blood screening, viral load monitoring, and disease diagnosis, and serve end-users including hospital laboratories, stand-alone labs, and others.

The hepatitis C testing market research report is one of a series of new reports that provides hepatitis C testing market statistics, including the hepatitis C testing industry global market size, regional shares, competitors with the hepatitis C testing market share, detailed hepatitis C testing market segments, market trends, opportunities, and any further data you may need to thrive in the hepatitis C testing industry. This hepatitis C testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hepatitis C testing market consists of revenues earned by entities by providing services such as laboratory-based HCV RNA testing, rapid diagnostic tests, and home-based HCV test kits. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis C testing market also includes sales of quality control materials, sample collection devices, and point-of-care (POC) diagnostic devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.